What Are the Early Signs of PML After Stopping Tysabri?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Targeted Risk Awareness

If you or a loved one has stopped taking Tysabri, you may wonder about the risk of progressive multifocal leukoencephalopathy (PML) and what early signs to watch for. The medical community has long recognized that certain therapies carry post-treatment risks, and the case of Tysabri-associated PML has shaped how doctors monitor patients after discontinuation. This page covers the symptoms, timeline, and FDA guidance on PML after stopping Tysabri.

Medical Evidence: Tysabri and PML Causation

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, highlighting this risk and mandating that the drug be available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is characterized by progressive neurological deficits, including cognitive impairment, motor dysfunction, and visual disturbances. Diagnosis typically involves brain imaging, cerebrospinal fluid analysis for JCV DNA, and biopsy in some cases. In Tysabri-treated patients, PML has been documented in clinical trials. Specifically, two cases occurred among 1869 multiple sclerosis patients treated for a median of 120 weeks, both of whom had also received interferon beta-1a. A third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore the causal link between Tysabri exposure and PML development.

Mechanistic Pathway and Risk Factors

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a humanized monoclonal antibody that binds to alpha-4 integrins, inhibiting leukocyte adhesion and migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for multiple sclerosis but also impairs immune surveillance against JCV. The JC virus, which is latent in many individuals, can reactivate and cause PML when T-cell-mediated immunity is compromised. Tysabri's effect on immune cell trafficking is believed to create an environment permissive for JCV replication and PML pathogenesis. Three key risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibody positivity indicates prior exposure to the virus and is associated with a higher risk of PML. Treatment duration beyond two years further elevates risk, likely due to prolonged immune modulation. Prior immunosuppressant use may compound immune dysfunction, increasing susceptibility. These factors should be considered when initiating and continuing Tysabri therapy, weighing expected benefits against PML risk.

FDA Warnings and Ongoing Surveillance

The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning and the TOUCH program. The boxed warning explicitly states that Tysabri increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH program restricts distribution to prescribers and patients who are enrolled and educated about PML risks. Despite these measures, PML cases continue to be reported, as reflected in FDA adverse event reports. The most frequently reported adverse events for Tysabri include fatigue, multiple sclerosis relapse, headache, and gait disturbance, but PML is a rare but severe outcome (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). Causation-related considerations for affected patients involve establishing a temporal relationship between Tysabri exposure and PML onset. The timeline between exposure and documented harm varies. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This suggests that PML can develop after both short-term and long-term use. For patients who develop PML, the prognosis is poor, with high rates of death or severe disability. Early detection and discontinuation of Tysabri are critical, but even with prompt action, outcomes are often unfavorable.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Tysabri and Progressive Multifocal Leukoencephalopathy (PML)?

Tysabri (natalizumab) is a monoclonal antibody used for multiple sclerosis and Crohn's disease. It increases the risk of PML, a severe brain infection caused by the JC virus. The FDA has issued a boxed warning due to this risk. Clinical trials documented PML cases in Tysabri-treated patients, establishing a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors increase susceptibility to PML by impairing immune surveillance against the JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How does the FDA regulate Tysabri to mitigate PML risk?

The FDA requires a boxed warning and a restricted distribution program called TOUCH. Prescribers and patients must be enrolled and educated about PML risks. Healthcare professionals must monitor for PML symptoms and discontinue Tysabri if suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.